Recombinant Proteins Market Size, Share & Trends Analysis Report By Host Cell (Insect Cells, Mammalian), By Application (Research, Therapeutics), By Product & Services, By End-user, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global recombinant proteins market size was valued at USD 1.75 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 12.00% from 2022 to 2030. The rising prevalence of chronic diseases, such as granulomatous disease, hemophilia, and sclerosis, is anticipated to drive industry growth. Furthermore, the rising preference for biologics as well as biosimilars, and enhanced recombinant protein products are some other factors contributing to the industry growth. The COVID-19 pandemic fueled the research and development race to find treatments and diagnostic tools for the SARS-CoV2 virus.

Recombinant technology played a major role during the initial phase, as a result of which, many recombinant proteins-based COVID-19 vaccines were developed with emergency use approval. For instance, in December 2021, the WHO issued a 9th COVID-19 vaccine for Emergency Use Listing (EUL). This EUL allowed vaccination access in low- and middle-income countries, such as Turkey, Colombia, Argentina, Mexico, Poland, South Africa, Iran, and Ukraine. Similarly, in June 2022, The Drugs Controller General of India (DCGI) approved the Covovax vaccine from the Serum Institute of India (SII) for children aged 7 to 12 years, which is a recombinant protein-based vaccine.

In addition to the actions taken to develop recombinant protein-based vaccines, intense efforts are being taken by multiple players for therapeutics via accelerated cycles of innovation to bring breakthroughs to patients faster. Furthermore, the demand for effective, efficient, and safe drugs enhanced the popularity of biopharmaceuticals. Moreover, the need for developing the COVID-19 vaccine on a large scale in minimal time along with its continuous commercial manufacturing activities had a positive impact as well as encouraging biologics-based research activities and eventually supported the industry growth.

As per Global Genes, more than 400 million people around the globe are suffering from rare genetic diseases. This number explains the dire need for treatments and the betterment of clinical settings as well as health awareness. The need for advanced research and drug targeting mechanisms’ knowledge is a crucial tool for medicine development. Many regions have developed biobanks from cohort programs to provide researchers with high-quality samples for revolutionizing treatment efforts. This can result in an increased focus on biomarkers discovery for various conditions. For instance, in August 2022, Ayvakit was given FDA approval to treat advanced systemic mastocytosis, a rare blood condition.

Ayvakit is the only medication that has been approved to target the KIT D816V mutation, which is responsible for almost all cases of Systemic Mastocytosis (SM). The development of personalized medicines and recombinant protein manufacturing is expected to witness an increase over the forecasted period. With this, the availability of research funding is expected to increase in the coming years. In a 2021 survey of the R&D world, almost 50% of respondents revealed that they saw their R&D budgets rise from 2020 to 2021 and nearly 60% of researchers expect their budgets to increase in 2022 from 2021.

This is expected to have a positive impact on the industry's growth. Key players are investing in their R&D programs to increase research productivity and grow their offerings for revenue generation. For instance, Merck KGaA spent USD 2.44 billion (EUR 2.4 billion) in research and development in 2021, in which, healthcare and life sciences dominated the expenditure costs. Such instances are expected to further support the case of growth in R&D activities and demonstrate the vision of companies to deliver a difference to the patients. Such initiatives by companies are likely to supplement the industry growth in the coming years.

Product & Services Insights

The product segment dominated the global industry in 2021. The segment accounted for the highest share of more than 65.70% of the overall revenue in the same year. The segment is anticipated to expand further at the second-fastest growth rate maintaining the leading position throughout the forecast period. The growth of this segment is a result of the extensive product usage in the fields of cancer, HIV/AIDS, COVID-19, immunology, and neuroscience, among others. Furthermore, growth factors and cytokines play a significant role in cancer research.

Study regarding the usage of growth factors in the treatment of cancer has improved the understanding and has given rise to new goals for chemotherapy. In addition, the need for recombinant protein products in regenerative medicine as well as rising financing for research & development in the fight against cancer are driving up the demand across the globe. On the other hand, the services segment has been estimated to register the fastest growth rate during the forecast period.

Application Insights

The therapeutics segment dominated the global industry in 2021 and accounted for the maximum share of more than 33.90% of the overall revenue. The segment is also estimated to register the fastest growth rate during the forecast period. The demand for protein-based treatment is anticipated to rise as the prevalence of diseases, such as metabolic disorders, cancer, genetic disorders, and immune diseases rises. In addition, cancer is one of the leading causes of mortality globally, and the World Health Organization (WHO) predicts a significant rise in cancer cases in the coming years.

As a result, it is projected that the industry for therapeutics would experience growth. On the other hand, protein therapeutics offer highly effective treatments for illnesses like diabetes, cancer, infectious disorders, hemophilia, and anemia. As per the International Diabetes Federation, 537 million persons (20-79 years old) are estimated to have diabetes in 2021. According to projections, there would be 643 million diabetics worldwide by 2030 and 783 million by 2045. With such growth in the diabetic population, the demand for recombinant proteins in the therapeutics segment is likely to show lucrative growth in the coming years.

Host Cell Insights

On the host cells, the global industry has been further categorized into mammalian systems, insect cells, yeast & fungi, bacterial cells, and others. The mammalian host cell segment dominated the global industry in 2021 and accounted for the highest revenue share of more than 41.70% of the overall revenue. The segment is estimated to expand further at the fastest growth rate maintaining its leading industry position throughout the forecast period. Mammalian protein expression is becoming increasingly popular as the market for proteomics & biologics expands.

Since they are provided easily, protein expression systems are simple to include in high throughput systems for effective biologics and proteomics investigations. Moreover, the focus on producing biopharmaceutical goods has increased as a result of factors, such as the rising incidence and prevalence of cancer and rising research & development (R&D) efforts, which are driving the industry expansion. The bacterial cells segment is estimated to register the second-fastest growth rate during the forecast period.

End-user Insights

The pharma & biotech companies segment captured the highest revenue share in 2021. The segment is estimated to expand further at the fastest CAGR during the forecast period retaining its leading position. The inclination toward biologics and biosimilars has resulted in a cascade of multi-million investments by the bio-manufacturers in R&D for growing the pipeline of products, devising new technologies, and advancing bioprocessing tools. The increasing demand, rising competition among players, and various applications by end-users have also attributed to the advancements in recombinant protein products.

In addition, the R&D sector also witnessed increased investments in terms of collaboration & partnerships between academia and industries. For example, Pfizer’s Center for Therapeutic Innovation (CTI) is a platform for collaboration within the healthcare ecosystem. CTI actively collaborates with academic institutes and investigators to tackle the challenges using Pfizer’s concepts. Collaborations like these fuel the drug development research and potential therapies for patients eventually propelling the industry growth.

Regional Insights

North America dominated the global industry in 2021 and accounted for the maximum share of more than 33.85% due to the rising research spending, availability of healthcare infrastructure, and presence of a number of industry players. In addition, recombinant proteins are one of the tested treatments for such disorders, therefore the chronic diseases that are spreading throughout the region are producing high demand for recombinant protein therapies. As per the GLOBOCAN estimates, in Mexico, in 2020, there were 90,222 cancer-related deaths and 1,95,499 newly diagnosed cancer cases.

To combat the pandemic, a number of major pharmaceutical companies in the U.S. have made investments in recombinant DNA technology and proteins. In April 2020, Sanofi & GSK collaborated on the development of vaccines using GSK’s additive technique as well as Sanofi’s recombinant S-protein COVID-19 antigens. In addition, several acquisitions are taking place to advance R&D for the production of recombinant proteins. The Asia Pacific region is also expanding due to an increase in public and private funding for research and development for recombinant protein studies, favorable government regulations, and the rising prevalence of target diseases with an aging population. In addition, the development of advanced techniques in proteomic and genomic research is propelling the region’s growth.

Key Companies & Market Share Insights

Key players are implementing various strategies including partnerships through mergers and acquisitions, geographical expansions, and strategic collaborations to expand their industry presence. For instance, in April 2019, Elpiscience BioPharma worked in conjunction with Bio-Techne Corp. (U.S.) (China). Through this partnership, Elpiscience would have access to Bio-extensive Techne’s product range of recombinant antibodies for the use in the production of preclinical, clinical, & commercial biopharmaceuticals to create anticancer treatments. Some of the key players in the global recombinant proteins market include:

• Abcam plc.

• Sino Biological, Inc.

• R&D Systems, Inc.

• GenScript

• Bio-Rad Laboratories, Inc.

• Merck KGaA

• Thermo Fisher Scientific

• Proteintech Group, Inc.

• Enzo Life Sciences, Inc. 

• Abnova Corp.

• RayBiotech Life Inc.

• STEMCELL Technologies Inc.

Recombinant Proteins Market Report Scope

Global Recombinant Proteins Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global recombinant proteins market report based on product & services, application, end-user, host cell, and region:

• Product & Services Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Product

    • Cytokines & Growth Factors

      • Interferons (IFNs)

      • Interleukins (ILs)

      • Others

    • Antibodies

    • Immune Checkpoint Proteins

    • Virus Antigens

    • Enzymes

      • Kinases

      • Metabolic enzymes

      • Others

    • Recombinant Regulatory Protein

    • Hormones

    • Others

  • Production Services

• Application Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Drug Discovery & Development

  • Therapeutics

    • Biologics

    • Vaccines

    • Cell & Gene Therapies

    • Others

  • Research

  • Others

• End-user Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharma & Biotechnology Companies

  • Academic & Research Institutes

  • Diagnostic Laboratories

  • Others

• Host Cell Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Mammalian Systems

  • Insect Cells

  • Yeast & Fungi

  • Bacterial Cells

  • Others

• Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE